

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 405/12, A61K 31/40, 31/535		A1	(11) International Publication Number: WO 99/51592 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/US99/07606			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 7 April 1999 (07.04.99)			
(30) Priority Data: 09/057,244 8 April 1998 (08.04.98) US			
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralta Farms, Madison, NJ 07940-0874 (US).			
(72) Inventors: MEWSHAW, Richard, Eric; 21 Boxwood Drive, Princeton, NJ 08512 (US). ZHOU, Ping; 28 Marion Drive, Plainsboro, NJ 08536 (US).			
(74) Agents: NAGY, Michael, R.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.			
(54) Title: INDOL-3-YL-CYCLOHEXYL AMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION (5-HT1 RECEPTOR ANTAGONISTS)			<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(57) Abstract			<p>Compounds effective in treating disorders of the serotonin-affected neurological symptoms (5-HT1A receptor active) are provided, such compounds having formula (I), wherein: R₁ and R₅ are each, independently, hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or trifluoromethyl; R₂ and R₄ are each, independently, hydrogen, lower alkyl, phenyl, or substituted phenyl; R₃ is hydrogen or lower alkyl; and X and Y are each, independently, O, NR₆, or CH₂, wherein R₆ is hydrogen, lower alkyl, phenyl, or substituted phenyl; or pharmaceutically acceptable salts thereof.</p> <p style="text-align: center;"></p>

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INDOL-3-YL-CYCLOHEXYL AMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION (5-HT1 RECEPTOR ANTAGONISTS)

5 **FIELD OF INVENTION**

This invention relates to compounds useful for the treatment of diseases affected by disorders of the serotonin-affected neurological systems, such as depression and anxiety. More specifically, this invention relates to various indol-3-yl-cyclohexylamine derivatives useful for the treatment of such diseases.


10

BACKGROUND OF INVENTION


Pharmaceutical compounds which enhance the transmission of serotonin (5-HT) are useful for the treatment of many psychiatric disorders, including depression and anxiety. The first generation of non-selective serotonin-affecting drugs operated through a variety of physiological functions which cause them to possess numerous undesired side effects, such as blurred vision, dry mouth, and sedation. The more recently introduced compounds, the selective serotonin reuptake inhibitors (SSRIs), act predominately by inhibiting 5-HT, which is released at the synapses, from being actively removed from the synaptic cleft via a presynaptic serotonin transport carrier. 20 Since SSRIs require several weeks before they exert their full therapeutic effect, this 5-HT blockade mechanism cannot fully account for their therapeutic activity. It is speculated that this two week induction which occurs before a full antidepressant effect is observed, is due to the involvement of the 5-HT1A autoreceptors which suppress the firing activity of the 5-HT neurons, causing a dampening of the therapeutic effect. 25 Studies suggest that after several weeks of SSRI administration, a desensitization of the 5-HT autoreceptors occurs allowing a full antidepressant effect in most patients. Hence, it is believed that overriding the negative feedback with the 5-HT1A antagonists would increase and accelerate the clinical antidepressant response. Recent studies by Artigas et al., *Trends Neurosci.*, 19:378-383 (1996) suggest a combination of 5-HT1A 30 activity and inhibition of 5-HT uptake within a single molecular entity can achieve a more robust and fast-acting antidepressant effect.

- 2 -


U.S. Patent No. 3,058,980 discloses the preparation of compounds having the following formula which are claimed to exhibit analgesic activity.



5 PCT Patent No. WO 89-07596A discloses the preparation of compounds of the following formula which are active in a variety of central nervous system disorders, including depression and schizophrenia.




10 Lastly, U.S. Patent No. 4,612,312 discloses compounds of the following formula as being potentially useful as anxiolytic and antihypertensive agents.



SUMMARY OF THE INVENTION

15 The present invention is directed to novel molecules which have the ability to act concomitantly at the 5-HT1A autoreceptors and with the 5-HT transporter. Such compounds are, therefore, potentially useful for the treatment of depression and other serotonin disorders.

20 The compounds of the present invention are indol-3-yl-cyclohexyl amine derivatives represented by Formula I:



- 3 -

I

wherein:

R₁ and R₅ are each, independently, hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or trifluoromethyl;

5 R₂ and R₄ are each, independently, hydrogen, lower alkyl, phenyl, or substituted phenyl;

R₃ is hydrogen or lower alkyl; and

X and Y are each, independently, O, NR₆, or CH₂, wherein

R₆ is hydrogen, lower alkyl, phenyl, or substituted phenyl; or

10 pharmaceutically acceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

Preferably, the compounds of the present invention are those represented by Formula I, wherein:

15 R₁ and R₅ are each, independently, hydrogen, or halogen;

R₂ and R₄ are each hydrogen;

R₃ is hydrogen; and

X and Y are each, independently, O or NR₆, wherein R₆ is hydrogen; or

pharmaceutically acceptable salts thereof.

20

More specifically, the compounds of the present invention are selected from the following:

(3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine;

25 (3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine;

(3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine; and

(3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.

As used herein, the terms "lower alkyl" and "lower alkoxy" are meant to include straight and branched carbon chains containing 1-6 carbon atoms. The term "halogen" is meant to include fluorine, chlorine, bromine, and iodine. The "substituted phenyl" may include substitution by halogen, lower alkyl, lower alkoxy and cyano groups.

- 4 -


The compounds of Formula I also may be used in the form of a pharmaceutically acceptable acid addition salt having the utility of the free base. Such salts, prepared by methods well known to the art are formed with both inorganic or organic acids, for example: fumaric, maleic, benzoic, ascorbic, pamoic, succinic, 5 bismethylenesalicylic, methanesulfonic, ethanesulfonic, acetic, oxalic, propionic, tartaric, salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene-sulfonic, hydrochloric hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.

10

The compounds of the present invention may be prepared by any suitable method known to those skilled in the art. However, the present compounds may be prepared according to any one of Schemes 1-3 set forth below. In the Schemes, the intermediate compounds exemplified hereinafter are identified in parenthesis. The 15 compound produced in each of the Schemes is identified by reference to the appropriate Example.

The compounds of Formula I are generally prepared by the overall sequence indicated in Schemes 1-3 as follows. In the Schemes, the intermediate compounds 20 exemplified hereinafter are identified in parenthesis. The compound produced in each of Schemes 1 to 3 is identified by reference to the appropriate Example.


Scheme 1




25

- 5 -

Scheme 2



5 Scheme 3



The present invention will now be illustrated by reference to the following specific non-limiting examples.

- 6 -

INTERMEDIATE 1

4-(5-Fluoro-1H-3-indolyl)-cyclohex-3-en-one ethylene ketal

5-Fluoroindole (5.4 g, 0.04 mol), 1,4-cyclohexanedione monoethylene ketal (12.5 g, 0.08 mol) were placed in 60 ml of 2N potassium hydroxide methanolic solution. The reaction mixture were heated to reflux for 4 hours. The reaction was cooled and the product was isolated by filtration and washed with methanol to give 10.1 g (93%) of product as a white solid: mp 153-155°C.

INTERMEDIATE 2

4-(5-Fluoro-1H-3-indolyl)-cyclohexanone ethylene ketal

10 A mixture of 4-(5-fluoro-1H-3-indolyl)-cyclohex-3-en-one ethylene ketal (2.7 g, 0.01 mol) and 10% palladium on carbon (1.2 g) in ethanol (200 ml) was hydrogenated for 4 days. The catalyst was filtered off and the filtrate was concentrated. The product was dried under vacuum to afford 2.8 g (100 %) of product as a white 15 solid: mp 183-185°C.

INTERMEDIATE 3

4-(5-Fluoro-1H-3-indolyl)-cyclohexanone

20 A solution of 4-(5-fluoro-1H-3-indolyl)-cyclohexanone ethylene ketal (2.8 g, 0.01 mol) in 200 ml (1:1) tetrahydrofuran-hydrochloric acid (1N) was allowed to stir at room temperature for 16 hours. The mixture was concentrated to half volume. The aqueous was extracted with ethyl acetate. The organic extracts were washed with brine, dried (anhydrous sodium sulfate), and filtered. The crude product was purified by flash chromatography (40% ethyl acetate in hexane) to afford 2.1 g (91%) of 25 product as yellow solid: mp 112-114°C.

INTERMEDIATE 4

2,3-Dihydro-2H-benzo[1,4]oxazine-2-carboxylate ester

30 To a solution of 2-aminophenol (10.0 g, 0.089 mol) in acetone (100 ml) was added anhydrous potassium carbonate (15.2 g, 0.108 mol) followed by ethyl 2,3-dibromopropionate (23.6 g, 0.092 mol) in four portions at reflux temperature. The reaction mixture was stirred at reflux for 21 hours and cooled. The solid was removed by filtration and the filtrate was concentrated. The residue was dissolved in cold 1N sodium hydroxide and extracted with ethyl ether. The combined organic extracts were 35 washed with brine, dried (anhydrous sodium sulfate), filtered, and concentrated. Chromatography (ethyl acetate/hexane: 1/2) afforded 6.25 g (34.4 %) of product as a brown oil:

- 7 -

INTERMEDIATE 5**3,4-Dihydro-2H-benzo[1,4]oxazin-2-yl)-methanol**

To a solution of ethyl 2,3-dihydro-2H-benzo[1,4]oxazine-2-carboxylate ester (11.9 g, 19.0 mmol) in anhydrous tetrahydrofuran (60 mL) was added a 2 M solution of lithium borohydride (15 mL) at room temperature. The reaction was allowed to stir for 1 hour and then quenched by the slow addition of methanol. After 2 hours, water was slowly added (100 mL) and the reaction mixture was extracted with ethyl acetate (4 x 100 mL). The organic layer was separated and dried over anhydrous magnesium sulfate, filtered, and the solvent removed under vacuum. Purification by chromatography (ethyl acetate/hexane/methanol: 3/6/1) afforded 1.96 g (62 %) of product as an oil: MS (EI) *m/e* 165 (M+).

INTERMEDIATE 6**15 2-Hydroxymethyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylic acid
tert-butyl ester**

To a solution of 3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-methanol (10.7 g, 65.0 mmol) in anhydrous tetrahydrofuran (200 mL) was slowly added di-tert-butyl bicarbonate (62 g) in tetrahydrofuran (40 mL). The reaction was heated to reflux for 4 hours, allowed to cool to room temperature and then poured into water (100 mL) and extracted with ethyl ether (3 x 100 mL). The organic layer was washed with water (2 x 50 mL), dried over anhydrous sodium sulfate, filtered, and the solvent removed under vacuum. Chromatography (ethyl acetate/hexane: 1/2) afforded 12.9 g of product as white solid (75 %): mp 93.5-94.5 °C; MS (EI) *m/e* 265 (M+).

25 Elemental analysis for $C_{14}H_{19}NO_4$

Calc'd: C, 63.38; H, 7.22; N, 5.28.

Found: C, 63.53; H, 7.32; N, 5.38

INTERMEDIATE 7**30 t-Butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-
methyltosylate**

To a solution of 2-hydroxymethyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester (80 mg, 0.3 mmol) and p-toluenesulfonyl chloride (86 mg) in anhydrous pyridine (15 mL) was allowed to stir overnight at room temperature. The reaction mixture was quenched with 1N HCl (20 mL) and extracted with methylene chloride (3 x 20 mL). The organic layer was washed with 1N HCl (2 x 20 mL) and the organic layer dried over anhydrous sodium sulfate, filtered and the solvent removed

- 8 -

under vacuum. Chromatography (ethyl acetate/hexane, 1/2) afforded 120 mg (94%) of product as a thick oil : MS (FAB) *m/e* 419 (M+Na).

Elemental analysis for C₂₁H₂₅NO₆S

5 Calc'd: C, 60.13; H, 6.01; N, 3.34.
 Found: C, 60.13; H, 6.11; N, 3.56

INTERMEDIATE 8

t-Butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-methylazide

10 A solution of t-butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-methyltosylate (14.2 g, 33.9 mmol) and sodium azide (4.4 g, 67.7 mmol) in anhydrous dimethylformamide (150 mL) was heated to 60 °C for 20 hours. The reaction mixture was poured into water (150 mL) and extracted with methylene chloride (3x150 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and the solvent removed under vacuum. Purification by chromatography (hexane) afforded
15 8.7 g (88 %) of product as a white solid: mp 82-83 °C.

Elemental analysis for C₁₄H₁₈N₄O₃

Calc'd C, 57.92; H, 6.25; N, 19.30.
 Found: C, 58.07; H, 6.21; N, 19.03

20 INTERMEDIATE 9

t-Butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-methylamine

25 A solution of t-butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-methylazide (6.25 g, 21.6 mmol) and triphenylphosphine (6.4 g) in tetrahydrofuran (150 mL) containing water (4 mL) was allowed to stir at room temperature for 18 hours. The solvent was removed under vacuum. The residue was dissolved in ethyl ether (100 mL). After addition of hexane (50 mL), the precipitated triphenylphosphine oxide was filtered off. The filtrate was concentrated and the residue was purified by chromatography (5% methanol in methylene chloride) affording 7.2 g of product
30 (which contained a small amount of triphenylphosphine oxide).: MS (FAB) *m/e* 265 (M+H⁺).

INTERMEDIATE 10

(t-Butyl-3,4-dihydro-benzo[1,4]oxazine-4-carboxylate-2-methyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine

35 A solution of 4-(5-fluoro-1H-indol-3-yl)-cyclohexanone (0.74 g, 3.2 mmol), t-butyl-2,3-dihydro-2H-benzo[1,4]oxazine-4-carboxylate-2-methylamine (0.80 g, 3.02

- 9 -

mmol), sodium triacetoxyborohydride (1.0 g, 4.5 mmol) and acetic acid (0.18 ml, 3.2 mmol) in 1,2-dichloroethane (14 ml) was allowed to stir at room temperature for 1.5 hours. The reaction was quenched with 1N sodium hydroxide, extracted with methylene chloride. The combined organic extracts were washed with brine, dried 5 (anhydrous sodium sulfate), filtered and concentrated. Chromatography (ethyl acetate/hexane: 3/7 to 5/5) afforded 1.40 g of the title compound product as a cis/trans mixture which was used without further separation.

10

EXAMPLE 1

(3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine and (3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine

To a solution of cis/trans-(t-butyl-3,4-dihydro-benzo[1,4]oxazine-4-carboxylate-2-methyl)-[4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine in methylene chloride (15 ml) was added trifluoroacetic acid (5 ml) at room temperature. After stirring the reaction mixture at room temperature for 2 hours, the solvent was removed. To the residue was added a small amount of methanol, the solution was adjusted to pH>9 with 2N NaOH. The aqueous was extracted with methylene chloride. The 15 combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The product was purified by chromatography (EtOAc/MeOH/NH₄OH: 99/1/0.5) to afford 0.41 g (35%) of the cis isomer as white solid: mp 65-67 °C. The HCl salt of the cis isomer was prepared in ethyl acetate: mp 20 120 °C (dec)

25 Elemental analysis for C₂₃H₂₆FN₃O•2HCl

Calc'd: C, 61.06; H, 6.24; N, 9.29.

Found: C, 61.06; H, 6.40; N, 8.71

30 The trans isomer was isolated in 19% yield (0.22 g) as a white solid: 66-68 °C. The HCl salt of the trans isomer was prepared in ethyl acetate: mp 155 °C (dec).

Elemental analysis for C₂₃H₂₆FN₃O•HCl•0.75H₂O•0.33EtOH

Calc'd: C, 63.71; H, 6.85; N, 9.16.

Found: C, 63.40; H, 6.70; N, 8.97

- 10 -

EXAMPLE 2

(3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine and (3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine

5 A solution of 4-(5-fluoro-1H-indol-3-yl)-cyclohexanone (0.578 g, 2.5 mmol), 3-aminomethyl-1,4-benzoxazine (0.411 g, 2.5 mmol), sodium triacetoxyborohydride (0.78 g, 3.5 mmol) and acetic acid (0.14 ml, 2.5 mmol) in 1,2-dichloroethane (11 ml) was allowed to stir at room temperature for 5 hours. The reaction was quenched with 1N sodium hydroxide, extracted with methylene chloride. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The product was purified by chromatography (EtOAc/MeOH/NH₄OH: 99/1/0.5) to afford 0.63 g (66%) of the cis isomer as an oil. The fumarate salt of the cis isomer was prepared in isopropanol: mp 208-209 °C.

Elemental analysis for C₂₃H₂₆FN₃O•0.5C₄H₄O₄•0.3H₂O•0.24*i*-PrOH

15 Calc'd: C, 67.55; H, 6.73; N, 9.19.
 Found: C, 67.75; H, 6.69; N, 8.99

The trans isomer was isolated in 33% yield (0.32 g) as an oil. The fumarate salt of the trans isomer was prepared in isopropanol: mp 275-277 °C (dec).

20 Elemental analysis for C₂₃H₂₆FN₃O•0.5C₄H₄O₄•0.3H₂O
 Calc'd: C, 67.79; H, 6.51; N, 9.49.
 Found: C, 67.58; H, 6.47; N, 9.18

25 The activity of the present compounds is demonstrated by the following standard pharmacological test procedures.

The PCR cloning of the human 5-HT_{1A} receptor subtype from a human genomic library has been described previously Chanda et al., *Mol. Pharmacol.*, 43:516 (1993). A stable Chinese hamster ovary cell line expressing the human 5-HT_{1A} receptor subtype 30 (5-HT_{1A}.CHO cells) was employed throughout this study. Cells were maintained in DMEM supplemented with 10% foetal calf serum, non-essential amino acids and penicillin/ streptomycin.

35 Cells were grown to 95-100% confluence as a monolayer before membranes were harvested for binding studies. Cells were gently scraped from the culture plates, transferred to centrifuge tubes, and washed twice by centrifugation (2000 rpm for 10 min., 4°C) in buffer (50 mM Tris; pH 7.5). The resulting pellets were aliquoted and

- 11 -

placed at -80°C. On the day of assay, the cells were thawed on ice, and resuspended in buffer. Studies were conducted using [³H]8-OH-DPAT as the radioligand. The binding assay was performed in 96 well microtiter plates in a final total volume of 250 μ L of buffer. Competition experiments were performed by using 7 concentrations of 5 unlabelled drug and a final ligand concentration of 1.5 nM. Non-specific binding was determined in the presence of 10 μ M 5HT. Saturation analysis was conducted by using [³H]8-OH-DPAT at concentrations ranging from 0.3-30 nM. Following a 30 minute incubation at room temperature, the reaction was terminated by the addition of ice cold buffer and rapid filtration using a M-96 Brandel Cell Harvester (Gaithersburg, MD) 10 through a GF/B filter presoaked for 30 minutes in 0.5% polyethyleneimine.

A protocol similar to that used by Cheetham et al., Neuropharmacol., 32:737 (1993) was used to determine the affinity of compounds for the serotonin transporter. Briefly, frontal cortical membranes prepared from male Sprague-Dawley rats were 15 incubated with ³H-paroxetine (0.1 nM) for 60 min at 25°C. All tubes also contained either vehicle, test compound (one to eight concentrations), or a saturating concentration of fluoxetine (10 μ M) to define specific binding. All reactions are terminated by the addition of ice cold Tris buffer followed by rapid filtration using a Tom Tech filtration device to separate bound from free ³H-paroxetine. Bound 20 radioactivity was quantitated using a Wallac 1205 Beta Plate[®] counter. Nonlinear regression analysis was used to determine IC₅₀ values which were converted to Ki values using the method of Cheng and Prusoff, Biochem. Pharmacol., 22:3099 (1973); Ki = IC₅₀/((Radioligand conc.)/(1 + KD)).

25 The [³⁵S]-GTP γ S binding assay was similar to that used by Lazarenko and Birdsall, Br. J. Pharmacol. 109:1120 (1993). Briefly, 5-HT_{1A} cloned receptor membrane fragments (as used for 5-HT_{1A} receptor binding assays) were stored at -70 °C until needed. When needed, membranes were rapidly thawed, centrifuged at 40,000 x g for 10 minutes and resuspended at 4 °C for 10 minutes in assay buffer (25 mM 30 HEPES, 3 mM MgCl₂, 100 mM NaCl, 1 mM EDTA, 10 uM GDP, 500 mM DTT, pH 8.0). These membranes were then incubated for 30 min at 30 °C with [³⁵S]GTPgS (1 nM) in the presence of vehicle, test compound (one to eight concentrations), or excess 8-OH-DPAT to define maximum agonist response. All reactions are terminated by the addition of ice cold Tris buffer followed by rapid filtration using a Tom Tech[®] filtration

- 12 -

device to separate bound from free [³⁵S]GTPgS. Agonists produce an increase in the amount of [³⁵S]GTPgS bound whereas antagonists produce no increase in binding. Bound radioactivity was counted and analyzed as above.

5 The following assays were performed by incubating the cells with DMEM containing 25 mM HEPES, 5 mM theophylline and 10 μ M pargyline for a period of 20 minutes at 37°C. Functional activity was assessed by treating the cells with forskolin (1 μ M final concentration) followed immediately by test compound (6 concentrations) for an additional 10 min at 37°C. In separate experiments, 6 concentrations of antagonist 10 were preincubated for 20 min prior to the addition of 10 nM 8-OH-DPAT and forskolin. The reaction was terminated by removal of the media and addition of 0.5 ml ice cold assay buffer. Plates were stored at -20°C prior to assessment of cAMP formation by a cAMP SPA assay (Amersham).

15 The results of the tests with the compounds of Examples 1 and 2 are given in the following table.

Example	Ki (nM) ST [³ H]paroxetine	Ki (nM) 5HT1A [³ H]DPAT
1 (cis)	44	2432
1 (trans)	24	44% @ 1 μ M
2 (cis)	34% @ 1 μ M	9% @ 1 μ M
2 (trans)	10	20% @ 1 μ M

20 The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In 25 tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Any of the solid carriers known to those skilled in the art may be used with the compounds of this invention. Particularly suitable solid carriers include, for example, calcium phosphate,

- 13 -

magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

5 Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs of the compounds of this invention. The compounds of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as

10 solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric

15 alcohols and polyhydric alcohols, e.g., glycols) and their derivatives and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

20 Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration may be either liquid or solid composition form.

25 Preferably, the pharmaceutical compositions containing the compounds of this invention are in unit dosage form, e.g., tablets or capsules. In such form, the compositions may be sub-divided in unit doses containing appropriate quantities of the present compounds. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing

30 liquids. Alternatively, the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

35 The therapeutically effective amount of the compounds of this invention that is administered and the dosage regimen depends on a variety of factors, including the weight, age, sex, and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the specific compound employed, and thus

- 14 -


may vary widely. However, it is believed that the pharmaceutical compositions may contain the compounds of this invention in the range of about 0.1 to about 2000 mg, preferably in the range of about 0.5 to about 500 mg and more preferably between about 1 and about 100 mg. Projected daily dosages of active compound are about 0.01
5 to about 100 mg/kg body weight. The daily dose can be conveniently administered two to four times per day.

The present invention may be embodied in other specific forms without departing from the spirit and essential attributes thereof and accordingly, reference
10 should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

- 15 -

WHAT IS CLAIMED IS:

1. A compound of the formula



5

wherein:

R₁ and R₅ are each, independently, hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or trifluoromethyl;

10 R₂ and R₄ are each, independently, hydrogen, lower alkyl, phenyl, or substituted phenyl;

R₃ is hydrogen or lower alkyl; and

X and Y are each, independently, O, NR₆, or CH₂, wherein

R₆ is hydrogen, lower alkyl, phenyl, or substituted phenyl; or pharmaceutically acceptable salts thereof.

15

2. A compound according to claim 1 wherein:

R₁ and R₅ are each, independently, hydrogen, halogen;

R₂ and R₄ are each hydrogen;

R₃ is hydrogen; and

20 X and Y are each, independently, O or NR₆, wherein R₆ is hydrogen; or pharmaceutically acceptable salts thereof.

25

3. The compound according to claim 1, which is (3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.

4. The compound according to claim 1, which is (3,4-Dihydro-benzo[1,4]oxazine-2-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.

30


5. The compound according to claim 1, which is (3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[cis-4-(5-fluoro-1H-indol-3-yl)cyclohexyl]-amine.

- 16 -

6. The compound according to claim 1, which is (3,4-Dihydro-benzo[1,4]oxazine-3-ylmethyl)-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.

7. A pharmaceutical composition comprising a compound of the formula

5



wherein:

R₁ and R₅ are each, independently, hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or trifluoromethyl;

10 R₂ and R₄ are each, independently, hydrogen, lower alkyl, phenyl, or substituted phenyl;


R₃ is hydrogen or lower alkyl; and

X and Y are each, independently, O, NR₆, or CH₂, wherein

R₆ is hydrogen, lower alkyl, phenyl, or substituted phenyl;

15 or pharmaceutically acceptable salts thereof.

8. A method for alleviating the symptoms of depression in a patient in need thereof, comprising administering to said patient an antidepressant effective amount of a compound of the formula



20

wherein:

R₁ and R₅ are each, independently, hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or trifluoromethyl;

R₂ and R₄ are each, independently, hydrogen, lower alkyl, phenyl, or substituted phenyl;

R₃ is hydrogen or lower alkyl; and

X and Y are each, independently, O, NR₆, or CH₂, wherein

R₆ is hydrogen, lower alkyl, phenyl, or substituted phenyl;

or pharmaceutically acceptable salts thereof.

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/US 99/07606

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D405/12 A61K31/40 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 666 258 A (SQUIBB BRISTOL MYERS CO) 9 August 1995 (1995-08-09) the whole document ----	1-10
Y	EP 0 714 894 A (LILLY CO ELI) 5 June 1996 (1996-06-05) the whole document ----	1-10
Y	WO 96 29075 A (LILLY CO ELI ;AUDIA JAMES E (US); DRESSMAN BRUCE A (US); DROSTE JA) 26 September 1996 (1996-09-26) the whole document ----	1-10
Y	WO 91 12252 A (NOVONORDISK AS) 22 August 1991 (1991-08-22) the whole document ----	1-10 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 September 1999

Date of mailing of the international search report

22/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/07606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 303 506 A (GLAXO GROUP LTD) 15 February 1989 (1989-02-15) the whole document ---	1-10
Y	EP 0 478 954 A (MERRELL DOW PHARMA) 8 April 1992 (1992-04-08) the whole document ---	1-10
Y	US 4 612 312 A (HIBERT MARCEL ET AL) 16 September 1986 (1986-09-16) cited in the application the whole document ---	1-10
Y	US 3 058 980 A (BERG, A.) 16 October 1962 (1962-10-16) the whole document ---	1-10
Y	SLEIGHT A J ET AL: "IDENTIFICATION OF 5-HYDROXYTRYPTAMINE1A RECEPTOR AGENTS USING A COMPOSITE PHARMACOPHORE ANALYSIS AND CHEMICAL DATABASE SCREENING" NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 343, 1 January 1991 (1991-01-01), pages 109-116, XP000650292 the whole document ---	1-10
Y	CLIFFE, I. A. ET AL.: "Advances in 5-HT1A Antagonist Search" DRUGS FUTURE, vol. 18, 1993, pages 631-642, XP002114577 BARCELONA the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/07606

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0666258	A 09-08-1995	US 5468768 A		21-11-1995
		AU 690163 B		23-04-1998
		AU 1001995 A		13-07-1995
		JP 7206818 A		08-08-1995
		US 5583149 A		10-12-1996
EP 0714894	A 05-06-1996	US 5521197 A		28-05-1996
		CA 2161209 A		02-06-1996
		JP 8225568 A		03-09-1996
WO 9629075	A 26-09-1996	AU 702322 B		18-02-1999
		AU 5311296 A		08-10-1996
		BR 9601061 A		06-01-1998
		CA 2215322 A		26-09-1996
		CN 1184425 A		10-06-1998
		CZ 9702888 A		18-02-1998
		EP 0733628 A		25-09-1996
		HU 9800417 A		28-06-1999
		JP 11502816 T		09-03-1999
		NO 974220 A		04-11-1997
		NZ 305166 A		23-12-1998
		PL 322843 A		16-02-1998
		US 5708008 A		13-01-1998
WO 9112252	A 22-08-1991	DK 37790 A		14-08-1991
		AT 123283 T		15-06-1995
		AU 641482 B		23-09-1993
		AU 7326591 A		03-09-1991
		CA 2074727 A		14-08-1991
		DE 69110124 D		06-07-1995
		DE 69110124 T		18-01-1996
		DK 515462 T		02-10-1995
		EP 0515462 A		02-12-1992
		FI 923492 A		03-08-1992
		IE 69761 B		02-10-1996
		IL 97105 A		28-11-1994
		JP 5503525 T		10-06-1993
		PT 96757 A, B		31-10-1991
		US 5126363 A		30-06-1992
		US 5250538 A		05-10-1993
EP 0303506	A 15-02-1989	AT 92057 T		15-08-1993
		AU 611469 B		13-06-1991
		AU 2069288 A		16-02-1989
		CA 1310968 A		01-12-1992
		CY 1728 A		06-05-1994
		DE 3882614 A		02-09-1993
		DE 3882614 T		18-11-1993
		DK 455488 A		14-02-1989
		EP 0303507 A		15-02-1989
		ES 2058292 T		01-11-1994
		FI 883744 A, B,		14-02-1989
		GB 2208646 A, B		12-04-1989
		HK 86793 A		27-08-1993
		HU 9500631 A		28-11-1995
		IE 61488 B		02-11-1994
		JP 1131174 A		24-05-1989
		JP 1207288 A		21-08-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/07606

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
EP 0303506	A	JP JP KR LU LV NO PH PT US US	1911883 C 6033252 B 131327 B 90160 A 5736 A 174052 C 24976 A 88255 A, B 4997841 A 5066660 A	09-03-1995 02-05-1994 17-04-1998 14-01-1998 20-06-1996 09-03-1994 26-12-1990 30-06-1989 05-03-1991 19-11-1991	
EP 0478954	A	08-04-1992	US AU AU CA CN FI HU IL JP NO PT US US	5189179 A 641535 B 8266491 A 2049803 A 1059717 A, B 914065 A 208955 B 99306 A 4270264 A 175430 B 98800 A, B 5559143 A 5387604 A	23-02-1993 23-09-1993 05-03-1992 01-03-1992 25-03-1992 01-03-1992 28-02-1994 30-03-1995 25-09-1992 04-07-1994 31-08-1992 24-09-1993 07-02-1995
US 4612312	A	16-09-1986	AR AT AU AU CA DK EP FI GR IE JP JP JP PT	241161 A 49409 T 578962 B 4535385 A 1244418 A 344085 A, B, 0170213 A 852922 A, B, 851835 A 58073 B 1903700 C 6031222 B 61246180 A 80859 A, B	30-12-1991 15-01-1990 10-11-1988 06-02-1986 08-11-1988 31-01-1986 05-02-1986 31-01-1986 02-12-1985 30-06-1993 08-02-1995 27-04-1994 01-11-1986 01-08-1985
US 3058980	A		NONE		